Recent Transactions

16-May-19
$2.0 billion
United States flag
Target: 

Gannett Co., Inc.

flag not available

Advised Gannett Co., Inc., a media and marketing solutions company, in relation to an unsolicited acquisition proposal from and successful proxy contest with MNG Enterprises, Inc.

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

U.S. rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

30-Jun-07
$52.0 billion
Canada flag
Target: 

BCE Inc.

U.S.A., Canada flags
Acquiror: 
Teacher's Private Capital, Providence Equity Partners Inc. and Madison Dearborn Partners, LLC

Advised the Board of BCE on a review of a range of strategic alternatives that culminated in an agreement to sell to a consortium consisting of Teacher's Private Capital, Providence Equity Partners and Madison Dearborn Partners for $52.0 billion that was ultimately terminated

show all